Target intelligence / Profile preview

Syntaxin-binding protein 5 (STXBP5)

Target
STXBP5
Molecular classification
Other (SNARE complex-associated regulatory protein), Cytosolic regulatory protein, Exocytosis regulator
01

Overview

Syntaxin-binding protein 5 (STXBP5), also known as tomosyn, is a large cytosolic protein that regulates membrane fusion events in exocytosis, primarily by binding syntaxins, which are core components of the SNARE complex. In the nervous system, STXBP5 inhibits synaptic vesicle priming and neurotransmitter release, while in platelets and endothelial cells, it modulates regulated secretion (exocytosis) of granule contents, including von Willebrand factor and P-selectin. Animal studies show that loss of STXBP5 impairs platelet secretion and hemostasis, but increases endothelial exocytosis, highlighting its dual roles. Genetic variations in STXBP5 are associated with altered plasma vWF levels and risk of thrombotic disorders, implicating it as a regulatory factor in cardiovascular disease pathways, although it is not currently a direct therapeutic target[1][2][3][5].

Other names
TomosynTomosyn-1LLGL3Lethal(2) giant larvae protein homolog 3Nbla04300LGL3
02

Biological functions

Regulation of exocytosisNeurotransmitter releasePlatelet secretionEndothelial exocytosisSynaptic vesicle primingRegulation of vesicular trafficking
03

Disease associations

Cardiovascular disease (through association with thrombosis and hemostasis)Bleeding disorders/hemostasis defects (based on knockout mouse models)Potential involvement in neurodegenerative disease (through neurotransmitter release regulation; not directly established as causal)Other (GWAS associations with risk of venous thromboembolism and plasma von Willebrand factor levels)
04

Safety considerations

Deficiency in STXBP5 can lead to severe bleeding diathesis due to platelet secretion defectsOveractivity or loss of inhibition in endothelium may contribute to excessive von Willebrand factor release, predisposing to thrombotic events
05

Biomarkers

Genetic variants (e.g., SNPs) in STXBP5 associated with plasma von Willebrand factor (vWF) levels, which in turn serve as biomarkers for thrombotic risk

Beyond the preview

Go deeper on Syntaxin-binding protein 5 (STXBP5).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Syntaxin-binding protein 5 (STXBP5).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call